Publications by authors named "Tomas Pika"

Claim this Profile
T
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Alexandra Jungova, Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Tomas Pika

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.
Martin Stork, Jakub Radocha, Jana Mihalyova, Ivan Spicka, Tomas Pika

Ann Hematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.
Jiri Minarik, Ludek Pour, Vojtech Latal, Tomas Jelinek, Jan Straub, Tomas Pika

BMC Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Tomas Jelinek, Tomas Pika

Ann Hematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
Vladimir Maisnar, Ludek Pour, Ivan Spicka, Tomas Jelinek, Jiri Minarik, Tomas Pika

Clin Lymphoma Myeloma Leuk· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Meletios A Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika

Am J Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Viera Sandecka, Luděk Pour, Ivan Špička, Jiří Minařík, Jakub Radocha, Tomáš Pika

Neoplasma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
Martin Stork, Sabina Sevcikova, Tomas Jelinek, Jiri Minarik, Jakub Radocha, Tomas Pika

Biomedicines· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone metabolism parameters and their relation to cytogenetics in multiple myeloma.
Petra Krhovska, Tomas Pika, Jitka Proskova, Jana Balcarkova, Jana Zapletalova

Eur J Haematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Alessandro Gozzetti, Andrea Guarnieri, Elena Zamagni, Elena Zakharova, Daniel Coriu, Tomáš Pika

Am J Hematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Localised forms of pulmonary amyloidosis].
Eva Mnacakanová, Lenka Henzlová, Pavla Flodrová, Tomáš Pika

Vnitr Lek· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Viera Sandecká, Luděk Pour, Ivan Špička, Jiří Minařík, Jakub Radocha, Tomáš Pika

Eur J Haematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma.
Jiri Minarik, Tomas Szotkowski, Jan Hrbek, Petra Krhovska, Eva Buriankova, Tomas Pika

Clin Case Rep· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.
Eva Kriegova, Regina Fillerova, Jiri Minarik, Jakub Savara, Jirina Manakova, Tomas Pika

Sci Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub

BMC Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Roman Hájek, Viera Sandecka, Ivan Špička, Marc Raab, Hartmut Goldschmidt, Tomáš Pika

Br J Haematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Anna Petrackova, Jiri Minarik, Lenka Sedlarikova, Tereza Libigerova, Alzbeta Hamplova, Tomas Pika

Br J Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, Jiri Minarik, Ioannis Ntanasis-Stathopoulos, Tomas Pika

Ann Hematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites.
Dusan Holub, Pavla Flodrova, Tomas Pika, Patrik Flodr, Marian Hajduch

Biomed Res Int· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].
Zdeněk Adam, Eva Ozábalová, Petr Němec, Helena Bedáňová, Milan Kuman, Tomáš Pika

Vnitr Lek· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Jakub Radocha, Vladimír Maisnar, Luděk Pour, Ivan Špička, Jiři Minařík, Tomáš Pika

Cancer Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac amyloidosis: from clinical suspicion to morphological diagnosis.
Pavla Flodrova, Patrik Flodr, Tomas Pika, Jiri Vymetal, Dusan Holub

Pathology· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival.
Tomas Pika, Ute Hegenbart, Pavla Flodrova, Bettina Maier, Christoph Kimmich

Blood· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Jiri Minarik, Martin Novak, Patrik Flodr, Jana Balcarkova, Miroslava Mlynarcikova, Tomas Pika, Zuzana Pikalova

Eur J Haematol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis